BEVACZIUMAB PLUS FOSBRETABULIN IN RECURRENT OVARIAN CANCER: OVERALL SURVIVAL AND EXPLORATORY ANALYSES OF A RANDOMIZED PHASE II NRG ONCOLOGY/GYNECOLOGIC ONCOLOGY GROUP STUDY

OBJECTIVE: To explore the relationship between tumor size and response to combined anti-vascular targeted therapy using the anti-angiogenesis inhibitor, bevacizumab, and the tubulin-binding vascular disrupting agent, fosbretabulin. METHODS: An exploratory, post-hoc analysis of the randomized phase I...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Gynecol Oncol
Main Authors: Tewari, Krishnansu S., Sill, Michael W., Coleman, Robert L., Aghajanian, Carol, Mannel, Robert, DiSilvestro, Paul A., Powell, Matthew, Randall, Leslie M., Farley, John, Rubin, Stephen C., Monk, Bradley J.
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7789907/
https://ncbi.nlm.nih.gov/pubmed/32723679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.07.015
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker